Life Sciences Equipment & Instrumentation / Biotech Research Tools
Strategic Profile
The company's product portfolio is broken into five market segments: Fluidics, Laboratory Equipment & Supplies, Molecular Analysis, Cell Analysis, and Physiology. In summer 2025 the board was reconstituted with a new CEO appointed, and in December 2025 the company successfully refinanced its debt, obtaining a $40 million credit facility with BroadOak Capital.
Cyborg Score Rationale
Q4 2025 revenue was $23.7M with gross margin at 60% and adjusted EBITDA of $3.8M up 27% YoY. However, the company faces profitability challenges and recently underwent significant restructuring. Recent debt refinancing and manufacturing consolidation suggest management is executing a turnaround strategy, but execution risk remains.
Top Insights
Q4 2025 gross margin improved to 60% (high end) with adjusted EBITDA up 27% YoY, indicating positive operational momentum.
Manufacturing consolidation closing Holliston MA facility, shifting US production to Minneapolis, with completion targeted by Q1 2027 and expected $3-4M in annual savings thereafter.
Company targets year-over-year revenue growth and mid-to-high single-digit EBITDA growth in 2026 while prioritizing high-margin platforms and consumables expansion (55% recurring mix).
Stock is currently significantly undervalued by the market, similar to periods in 2019 and 2026.
Named Competitors
Electrophysiology Systems — Patch clamp and electrophysiology recording systems
Infusion Systems — Syringe pumps and peristaltic infusion equipment
Cellular Analysis Platforms — Microelectrode array systems and cellular analysis
Recent Developments
(Feb 2026) Q4 2025 preliminary results announced with $23.7M revenue and 60% gross margin exceeding guidance
(Dec 2025) Refinanced debt with $40M credit facility from BroadOak Capital; all loans mature Dec 17, 2029
(Jan 2026) Announced strategic manufacturing consolidation to close Holliston facility by Q1 2027 with $3-4M annual savings
(Nov 2025) Reported highest backlog in nearly two years with four consecutive months of order growth
Open the full interactive Harvard Bioscience, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.